Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI343 in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06238843Phase 3Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of arcotatug tavatecan in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Innovent Biologics. Primary endpoints: Progression-Free Survival at 20 months and Overall Survival at 26 months. Started Jun 2024; status: active, not recruiting.
02
Drugs
arcotatug tavatecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06238843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238843.